4 / 33
Page 56
Notes:
conferenceseries
.com
Volume 5, Issue 6(Suppl)
J Infect Dis Ther, an open access journal
ISSN: 2332-0877
Euro Infectious Diseases 2017
September 07-09, 2017
September 07-09, 2017 | Paris, France
Infectious Diseases
6
th
Euro-Global Conference on
Diabetes mellitus-related comorbidities among patients attending twomajorHIVclinics in Botswana:
A 12-year retrospective cohort study
Goabaone Rankgoane-Pono
1
, Jose Gaby Tshikuka
1,2
, Mgaywa Gilbert Mjungu Damas Magafu
1,3
, Tiny Masupe
1
, Mooketsi Molefi
1
, Shimeles Genna
Hamda
1
, Vincent Setlhare
1
, Roy Tapera
1
and
Bontle Mbongwe
1
1
University of Botswana, Botswana
2
National Pedagogic University, DRC
3
University of Washington, USA
Background:
An association between combination antiretroviral therapy (cART) and diabetes-related comorbidities (DRCs)
has been found in some countries. However, data on the incidence of DRCs among cART recipients in Botswana are not
available. The objectives of this study were to estimate the incidence of DRCs among cART recipients, assess the time-to-event
in the presence of censored cases and identify cART regimens most associated with DRCs.
Methods:
531 patients who were on cART at Princess Marina Hospital (PMH) HIV clinic and Bontleng HIV clinic were
identified and retrospectively followed for 12 years. Each of the 531 patients was on one of the three standard first-, second- or
third-line cART regimens. Person-years (PY) were used to compute the incidence of DRCs. Kaplan-Meier survival analysis was
performed to compare survival of first-line cART patients to that of second-line/third-line cART patients. Cox regression was
used to investigate associations with DRCs.
Results:
The incidence of DRCs was found to be 26.8/1000 PY, with total time of exposure of 3316 PY. The average duration to
event for all the 3 regimens was 11.72±0.20 years. The first-line cART regimen had a shorter mean ± SE duration of 10.59±0.26
years to the event compared to 12.69±0.24 years for the second-line/third-line regimen. Both the first-line cART and second-
line/third-line cART were associated with DRCs but recipients on the first-line cART had a significantly shorter survival than
recipients on second-line/third-line cART (Log-rank X2=8.98, p<0.003).
Conclusion:
Both the first-line cART and second-line/third-line cART were associated with DRCs but the risk of developing
DRCs per year of exposure was significantly greater for patients who were on first-line cART compared to those who were on
second-line/third-line cART. Close monitoring of current cART treatment in patients and possible development of DRCs and
other chronic non-communicable diseases is recommended in an effort to improve longevity and quality of life in people living
with HIV/AIDS.
Biography
Jose Gaby Tshikuka Mulumba, Department of Public Health Medicine, Faculty of Medicine, University of Botswana, Botswana. Her research is mainly focused on
Epidemiology, public health and Infectious Diseases.
jtshikuka@hotmail.comJose Gaby Tshikuka et al., J Infect Dis Ther 2017, 5:6(Suppl)
DOI: 10.4172/2332-0877-C1-033